---
title: "300765.SZ (300765.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300765.SZ/news.md"
symbol: "300765.SZ"
name: "300765.SZ"
parent: "https://longbridge.com/en/quote/300765.SZ.md"
datetime: "2026-05-20T10:12:42.994Z"
locales:
  - [en](https://longbridge.com/en/quote/300765.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300765.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300765.SZ/news.md)
---

# 300765.SZ (300765.SZ) — Related News

### [](https://longbridge.com/en/news/286527433.md)
*2026-05-15T07:54:16.000Z*
> The National Healthcare Security Administration issued implementation opinions on reforming and improving the supply gua

### [CSPC Innovation: The holding subsidiary SYS6010 is once again included in the list of breakthrough therapies](https://longbridge.com/en/news/285906246.md)
*2026-05-11T08:35:17.000Z*
> CSPC Innovation announced that its holding subsidiary, Jushi Biologics, has once again been included in the list of brea

### [CSPC Innovation released its first-quarter performance, with a net loss attributable to the parent company of 93.8547 million yuan, an increase of 248.88%](https://longbridge.com/en/news/284241747.md)
*2026-04-27T15:18:27.000Z*
> CSPC Innovation released its first-quarter report for 2026, with operating revenue of 665 million yuan, a year-on-year i

### [China’s drug makers are speeding up – will AI be their secret weapon?](https://longbridge.com/en/news/283216305.md)
*2026-04-18T08:04:42.000Z*
> China's pharmaceutical industry is rapidly evolving, with major companies like CSPC Pharmaceutical and RemeGen securing 

### [Under huge losses, why does CSPC Innovation still dare to stubbornly pursue innovative drugs?](https://longbridge.com/en/news/283107790.md)
*2026-04-17T07:45:16.000Z*
> CSPC Innovation reported its first loss in the 2025 financial report, with a net profit attributable to the parent compa

### [CSPC Innovation reports its first loss of 241 million yuan since going public, as caffeine "cash cow" turns into an innovative drug "money-burning" bottomless pit? | Financial Report Anomaly Perspective](https://longbridge.com/en/news/282968352.md)
*2026-04-16T08:23:11.000Z*
> CSPC Innovation reported its first major loss since going public, with a net profit loss of 241 million yuan in 2025, a 

### [CSPC PHARMA: SYS 6051 has received clinical trial approval in China](https://longbridge.com/en/news/282818370.md)
*2026-04-15T09:39:05.000Z*
> CSPC PHARMA announced that its developed SYS 6051 has been approved by the National Medical Products Administration of C

### [CSPC Innovation: SYS6051 injection has received approval for clinical trials](https://longbridge.com/en/news/282803848.md)
*2026-04-15T07:56:50.000Z*
> CSPC Innovation's holding subsidiary, Jushi Biologics, recently received approval from the National Medical Products Adm

### [](https://longbridge.com/en/news/282773359.md)
*2026-04-15T02:40:37.000Z*
> A-shares of innovative drugs strengthened, Huaren Health approached a 20% limit-up, Realcan, HISUN, JINLING PHARM., and